Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: Quantitative radiologic assessment and implications for management

Korean Journal of Radiology

Volumn 16, Issue 2, 2015, Pages 304-313

  Kim, Kyung Won ^a,b   Shinagare, Atul B ^a   Krajewski, Katherine M ^a   Pyo, Junhee ^c   Tirumani, Sree Harsha ^a   Jagannathan, Jyothi P ^a   Ramaiya, Nikhil H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Ascites; Computed tomography; Fluid retention; Imatinib; Subcutaneous edema

Indexed keywords

DIATRIZOATE; DIURETIC AGENT; IMATINIB; IOPROMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG MEGADOSE; EDEMA; FEMALE; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; PLEURA EFFUSION; RETROSPECTIVE STUDY; SCORING SYSTEM; VERY ELDERLY; ADULT; ADVERSE EFFECTS; ECHOCARDIOGRAPHY; GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TRACT; HEART FAILURE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERITONEAL NEOPLASMS; PROCEDURES; RADIOGRAPHY; RADIOLOGY; SECONDARY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASCITES; BENZAMIDES; ECHOCARDIOGRAPHY; EDEMA; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TRACT; HEART FAILURE; HUMANS; IMATINIB MESYLATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PERICARDIAL EFFUSION; PERITONEAL NEOPLASMS; PIPERAZINES; PLEURAL EFFUSION; PYRIMIDINES; RADIOLOGY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84923853767     PISSN: 12296929     EISSN: None     Source Type: Journal    
DOI: 10.3348/kjr.2015.16.2.304     Document Type: Article

References (22)

1. Siddiqui MA, Scott LJ. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 2007;67:805-820.
2. Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol 2012;86:1-12.
3. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
4. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-2011.
5. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.
6. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-632.
7. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006;26:481-495.
8. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011;37:75-88.
9. Kim KW, Choi HJ, Kang S, Park SY, Jung DC, Cho JY, et al. The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer. Eur J Radiol 2010;75:230-235.
10. Figueras J, Juncal A, Carballo J, Cortadellas J, Soler JS. Nature and progression of pericardial effusion in patients with a first myocardial infarction: relationship to age and free wall rupture. Am Heart J 2002;144:251-258.
11. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
12. Pinilla-Ibarz J, Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 2011;117:688-697.
13. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-942.
14. Ostro D, Lipton J. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia. Leuk Lymphoma 2007;48:195-196.
15. Van Glabbeke M, Verweij J, Casali PG, Simes J, Le Cesne A, Reichardt P, et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006;42:2277-2285.
16. Marrari A, Wagner AJ, Hornick JL. Predictors of response to targeted therapies for gastrointestinal stromal tumors. Arch Pathol Lab Med 2012;136:483-489.
17. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916.
18. Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007;43:974-978.
19. Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, Lenihan DJ, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010;116:184-192.
20. Heuchel R, Berg A, Tallquist M, Ahlén K, Reed RK, Rubin K, et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3’ kinase signaling. Proc Natl Acad Sci U S A 1999;96:11410-11415.
21. Pietras K, Ostman A, Sjöquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-2934.
22. Masiello D, Gorospe G 3rd, Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009;2:46.